Kaminskas LM - Search Results

1

From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity.

Trevaskis NL, Kaminskas LM, Porter CJ. Trevaskis NL, et al. Among authors: kaminskas lm. Nat Rev Drug Discov. 2015 Nov;14(11):781-803. doi: 10.1038/nrd4608. Epub 2015 Oct 16. Nat Rev Drug Discov. 2015. PMID: 26471369 Review.

2

Using Graph-Based Signatures to Guide Rational Antibody Engineering.

Ascher DB, Kaminskas LM, Myung Y, Pires DEV. Ascher DB, et al. Among authors: kaminskas lm. Methods Mol Biol. 2023;2552:375-397. doi: 10.1007/978-1-0716-2609-2_21. Methods Mol Biol. 2023. PMID: 36346604

3

Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats.

Subasic CN, Butcher NJ, Minchin RF, Kaminskas LM. Subasic CN, et al. Among authors: kaminskas lm. Mol Pharm. 2023 Jul 3;20(7):3494-3504. doi: 10.1021/acs.molpharmaceut.3c00104. Epub 2023 May 31. Mol Pharm. 2023. PMID: 37256791

4

Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats.

Boyd BJ, Kaminskas LM, Karellas P, Krippner G, Lessene R, Porter CJ. Boyd BJ, et al. Among authors: kaminskas lm. Mol Pharm. 2006 Sep-Oct;3(5):614-27. doi: 10.1021/mp060032e. Mol Pharm. 2006. PMID: 17009860

5

Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition.

Kaminskas LM, Boyd BJ, Karellas P, Henderson SA, Giannis MP, Krippner GY, Porter CJ. Kaminskas LM, et al. Mol Pharm. 2007 Nov-Dec;4(6):949-61. doi: 10.1021/mp070047s. Epub 2007 Oct 23. Mol Pharm. 2007. PMID: 17953445

6

The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.

Kaminskas LM, Boyd BJ, Karellas P, Krippner GY, Lessene R, Kelly B, Porter CJ. Kaminskas LM, et al. Mol Pharm. 2008 May-Jun;5(3):449-63. doi: 10.1021/mp7001208. Epub 2008 Apr 5. Mol Pharm. 2008. PMID: 18393438

7

Partly-PEGylated Poly-L-lysine dendrimers have reduced plasma stability and circulation times compared with fully PEGylated dendrimers.

Kaminskas LM, Wu Z, Barlow N, Krippner GY, Boyd BJ, Porter CJ. Kaminskas LM, et al. J Pharm Sci. 2009 Oct;98(10):3871-5. doi: 10.1002/jps.21692. J Pharm Sci. 2009. PMID: 19283758

8

Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.

Kaminskas LM, Kelly BD, McLeod VM, Boyd BJ, Krippner GY, Williams ED, Porter CJ. Kaminskas LM, et al. Mol Pharm. 2009 Jul-Aug;6(4):1190-204. doi: 10.1021/mp900049a. Mol Pharm. 2009. PMID: 19453158

9

PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats.

Kaminskas LM, Kota J, McLeod VM, Kelly BD, Karellas P, Porter CJ. Kaminskas LM, et al. J Control Release. 2009 Dec 3;140(2):108-16. doi: 10.1016/j.jconrel.2009.08.005. Epub 2009 Aug 15. J Control Release. 2009. PMID: 19686787

10

Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers.

Kaminskas LM, Kelly BD, McLeod VM, Sberna G, Boyd BJ, Owen DJ, Porter CJ. Kaminskas LM, et al. Mol Pharm. 2011 Apr 4;8(2):338-49. doi: 10.1021/mp1001872. Epub 2011 Jan 21. Mol Pharm. 2011. PMID: 21171585

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

87 results

Search Page